A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy

Breast Cancer Res Treat. 2019 Oct;177(3):691-703. doi: 10.1007/s10549-019-05334-5. Epub 2019 Jul 1.

Abstract

Background: Women with ER-positive breast cancer may recur as late as 20 years post-diagnosis. The reason for this delayed recurrence is unknown. We studied survival patterns, including time-to-death in 123,705 women with stage I to III invasive breast cancer, enrolled in the SEER database. Among these 76.8% were ER-positive and 23.2% were ER-negative.

Methods: We divided the cohort into ten classes with varying risks of death from breast cancer. The 20-year mortality for women in the highest risk decile 10 was 69% versus 5% for women in the lowest decile 1. The difference in the time-to-death by decile could be explained by a variable α which represents the annual rate of reactivation from tumour dormancy.

Results: The duration of tumour dormancy was much longer, on average, for ER-positive breast cancers than for ER-negative breast cancers. Reactivation from tumour dormancy appears to occur at random and may explain the very long time to cancer recurrence in women with small node-negative ER-positive breast cancers.

Conclusion: The clinical course of women with low-risk ER-positive breast cancer is inherently unpredictable and consequently death is equally as likely to occur at year 3 than at year 20.

Keywords: Breast cancer; Survival; Tumor dormancy.

MeSH terms

  • Adult
  • Age of Onset
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / etiology
  • Breast Neoplasms / mortality*
  • Breast Neoplasms / pathology*
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Mortality
  • Neoplasm Grading
  • Neoplasm Staging
  • Prognosis
  • SEER Program
  • Time Factors

Substances

  • Biomarkers, Tumor